Related Experiment Video
Updated: Aug 23, 2025
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
83.8K
The oral anticoagulants’ burden
Catherine Plotton1, Camille Mouyer1, Pierre Michelland1
1Département de médecine générale, Faculté de médecine Jacques Lisfranc, Saint-Étienne, France
Geriatrie Et Psychologie Neuropsychiatrie Du Vieillissement
|November 2, 2022
Summary
Oral anticoagulants significantly impact patient quality of life, with 41% experiencing treatment burden due to side effects, anxiety, or lifestyle changes. Understanding this burden is crucial for improving patient care and satisfaction with anticoagulant therapy.
Area of Science:
- Pharmacology
- Patient-Reported Outcomes
- Health Services Research
Context:
- Oral anticoagulants are essential for preventing thromboembolic events but can impose a significant burden on patients.
- Previous research has explored patient satisfaction with oral anticoagulants, but the specific treatment burden requires further investigation.
Purpose:
- To assess the treatment burden experienced by patients undergoing oral anticoagulant therapy.
- To identify factors contributing to the burden of anticoagulant treatment.
Summary:
- A cross-sectional study surveyed 389 patients receiving oral anticoagulants.
- The anti-clot treatment scale and Zarit scale were used to measure treatment satisfaction and burden.
- 41% of patients reported a burden from oral anticoagulants, particularly when experiencing side effects, anxiety, or lifestyle modifications.
Impact:
- Findings highlight that oral anticoagulants can be a considerable burden, affecting patient quality of life.
- Identifying specific burden factors can inform strategies to mitigate negative impacts and improve patient adherence and satisfaction.
- This research underscores the importance of considering the patient's holistic experience when managing anticoagulant therapy.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
849
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
849
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:29Venous Thrombosis III: Interprofessional Care
18
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
609
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
609
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
627
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
627